Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by rival Eli Lilly.
The Danish drugmaker said Tuesday that pre-filled pens and vials of long- and short-acting insulins will see list price reductions. They include Levemir, Novolin, NovoLog and NovoLog Mix70/30.Novo also will drop the list price of unbranded products like Insulin Aspart to match the lower price of the branded insulins.
Patient advocates have long called for insulin price cuts to help uninsured people who would not be affected by price caps tied to insurance coverage. They have noted that high insulin prices force many people to ration doses, which can be dangerous for their health. Insulin affordability in the United States depends largely on whether patients have health insurance and the details of that coverage. People with employer-sponsored coverage, for instance, may pay little out of pocket for their insulin or they might pay hundreds of dollars if they must first meet a high deductible before the coverage kicks in.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk to slash U.S. insulin prices by up to 75%, following move by Eli LillyNovo Nordisk is planning to slash the price of several insulin drugs by up to 75% in the U.S., following a similar move by Eli Lilly.
Read more »
Novo Nordisk plans to cut insulin prices up to 75%, following Eli LillyNovo will reduce the list price for NovoLog and NovoLog Mix 70/30 by 75%, and cut Novolin and Levemir’s list prices by 65% — but not until 2024.
Read more »
Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli LillyNovo Nordisk, along with Sanofi and Eli Lilly, make up most of the U.S. insulin market.
Read more »
WSJ News Exclusive | Novo Nordisk to Slash Insulin Prices by Up to 75%Breaking: Novo Nordisk, a large insulin maker, plans to cut the prices of its widely used products up to 75% to make them more affordable for patients. This follows a similar move by Eli Lilly.
Read more »
Novo Nordisk to Slash Insulin Prices by Up to 75%Novo Nordisk has announced plans to slash the price of several insulin drugs by up to 75% in the U.S., becoming the latest drugmaker to make sharp price cuts after years of public outrage over the high cost of diabetes care.
Read more »
Novo Nordisk plans to cut insulin prices in U.S. by up to 75%Drugmaker Novo Nordisk said on Tuesday it would cut list prices for several insulin drugs by up to 75% in the United States, starting Jan. 1, 2024.
Read more »